loader image
Saturday, February 24, 2024
76.7 F
McAllen
We Welcome your Press Release
- Advertisement -

Patients Treated with Immune Checkpoint Inhibitors Have Better Quality of Life, Moffitt Analysis Shows

Translate to Spanish or other 102 languages!

Immune checkpoint inhibitors that activate the immune system to target cancer cells have greatly impacted the lives of cancer patients. Image for illustration purposes.

Mega Doctor News

- Advertisement -

By Moffitt Cancer Center

Newswise — TAMPA, Fla. — Immune checkpoint inhibitors that activate the immune system to target cancer cells have greatly impacted the lives of cancer patients by improving survival and providing an alternative to chemotherapy. However, it is unclear how immune checkpoint inhibitors affect patients’ quality of life, symptoms and physical functioning. In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers report that patients treated with immune checkpoint inhibitors have a higher self-reported quality of life than patients treated with other types of therapy.

Immune checkpoint inhibitors are approved to treat a variety of solid tumor types and lymphomas. The therapy works by blocking the activity of the proteins PD-1, PD-L1 or CTLA-4, resulting in stimulation of the immune system and promotion of anti-tumor activity. Current immune checkpoint inhibitors include the drugs atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab and pembrolizumab.

- Advertisement -

There is limited information about how treatment with immune checkpoint inhibitors impacts a patient’s life, and how that compares to standard treatment options. In general, it is hoped that cancer treatments will ultimately improve the overall quality of life as the tumor recedes, and patients enter remission. However, all cancer therapies, including immune checkpoint inhibitors, are associated with side effects that could affect a patient’s daily life, such as their ability to work. Chemotherapy tends to be associated with more severe adverse events than targeted therapies such as immune checkpoint inhibitors because of the nondiscriminatory impact of chemotherapy on both cancer cells as well as normal cells. Ultimately, the anti-tumor activity of various treatment regimens combined with their associated side effects can result in both positive and negative effects on patients’ quality of life.

Graphic Source:  Cancer.gov

Moffitt researchers performed an extensive meta-analysis of 26 published studies that analyzed self-reported changes in quality of life, physical functioning and symptoms among patients treated with immune checkpoint inhibitors. Although many studies focus on symptoms assessed by doctors, the authors of this meta-analysis focused on patients’ own perceptions. Moffitt researchers analyzed self-reported outcomes of patients administered immune checkpoint inhibitors before and after treatment and compared that with patients who were treated with other therapies.

They discovered that in general, patients’ quality of life did not change significantly over time upon treatment with immune checkpoint inhibitors. However, quality of life was better among patients treated with immune checkpoint inhibitors when compared to patients treated with other therapies.

The researchers also assessed specific disease and treatment symptoms among the studies. They found that patients treated with immune checkpoint inhibitors reported less symptoms of appetite loss, insomnia, and pain severity, but increased symptoms of breathing difficulty. They did note that differences existed among the regimens and tumor types. For example, patients treated with the CTLA-4 inhibitor ipilimumab reported a worsening of quality of life, particularly among melanoma patients, whereas other immunotherapies were associated with either an improved or stable quality of life.

- Advertisement -

The research team hopes these findings will help patients better understand what to expect with checkpoint inhibitor therapy. “A growing number of patients are receiving immune checkpoint inhibitors and need evidence-based information regarding what to expect on treatment,” said Brian D. Gonzalez, Ph.D., lead author and associate member in the Department of Health Outcomes and Behavior at Moffitt. “This study is among the first to aggregate data about patient-reported outcomes of immunotherapy. These data can be used to reassure patients and their families that most can expect stable or improved global quality of life on average with PD-1/PD-L1 inhibitors and slight decrements in global quality of life in CTLA-4 inhibitors.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

PSJA ISD Student Leaders Annual Track of Hope Cancer Awareness Walk, Feb. 24th 

With many members of the PSJA community affected by cancer, PSJA ISD high school students organized the Track of Hope Cancer Awareness & Relief Walk event to help raise awareness and funds to give back.

Epidemiology Expert Dr. Scott Lillibridge Takes Helm at DHR Health Institute for Research and Development

Dr. Lillibridge's distinguished federal career with the Centers for Disease Control and Prevention (CDC) includes serving as Special Assistant to the Secretary for the Department of Health and Human Services, Director for the CDC Bioterrorism Preparedness and Response Program, and Medical Director for the US Office of Foreign Disaster Assistance (USAID).

Aida Coronado Garcia’s Back to the Beginning, A Day of Leadership at Perkins Middle School     

Coronado Garcia's visit was more than just a ceremonial return; it was an interactive and insightful activity into the daily operations and challenges of running a middle school.

New Cell-Based Immunotherapy Offered for Melanoma

Washington University doctors and researchers were involved in clinical trials that led to the FDA approval.
- Advertisement -
×